Pimavanserin (Nuplazid)

What it treats

Pimavanserin is FDA-approved for hallucinations and delusions associated with Parkinson's disease psychosis. That's a common and difficult problem: many people with Parkinson's disease develop psychotic symptoms over time, and treating them with standard antipsychotics tends to worsen tremor, rigidity, and bradykinesia because standard antipsychotics block dopamine, which is exactly the neurotransmitter Parkinson's medications are trying to boost. Pimavanserin's dopamine-free mechanism gets around that.

How it works

Pimavanserin acts at serotonin 5-HT2A receptors as an inverse agonist, which quiets their baseline activity. Elevated 5-HT2A signaling is one of the drivers of hallucinations, and pimavanserin's action on this pathway explains its antipsychotic effect without dopamine blockade.

Receptor mechanism (detail)

Pimavanserin is a selective 5-HT2A inverse agonist and antagonist with modest 5-HT2C affinity. It has no meaningful activity at dopamine, histamine, muscarinic, or adrenergic receptors. That receptor selectivity is why it doesn't cause the movement side effects, sedation, or orthostatic hypotension typical of other antipsychotics, and why it doesn't worsen Parkinson's motor symptoms.

Potency and typical dosing pattern

Ranges are typical framework only, not a prescription for any individual. Pimavanserin is dosed at a fixed 34 mg once daily, taken as two 17 mg capsules. No titration is needed.

Safety monitoring

• ECG at baseline and periodically. Pimavanserin prolongs QTc modestly.
• Blood pressure and orthostatic vitals at baseline and periodically.
• Motor symptom check in Parkinson's patients, watching for any worsening.
• Cognitive and behavioral assessment on ongoing visits.
• Metabolic labs aren't a major concern the way they are with dopamine-blocking antipsychotics, but weight and basic labs are still worth periodic checks.

Metformin co-commencement: Aoife Carolan / Schizophrenia Bulletin guideline.

A clinical guideline led by Aoife Carolan strongly recommends co-commencing metformin alongside high-risk antipsychotics like olanzapine or clozapine. This proactive approach helps mitigate severe metabolic side effects, significantly reducing antipsychotic-induced weight gain and improving insulin resistance. The Schizophrenia Bulletin guideline states that when prescribing olanzapine or clozapine, metformin should be initiated immediately to prevent weight gain and cardiometabolic issues. Pimavanserin isn't a dopamine-blocking antipsychotic and doesn't drive weight gain or metabolic changes typical of the class, so the co-commencement framework doesn't apply. Metformin would be considered only if metabolic issues developed for reasons unrelated to pimavanserin.

Typical titration used in the guideline: 500 mg once daily, then 500 mg twice daily after one week, then 500 mg increments every two weeks as tolerated, up to 1000 mg twice daily by about week six. Contraindicated with eGFR below 30 mL/min/1.73 m². Renal function is checked annually and metformin is held during acute illness or dehydration.

Source: Carolan A, et al. Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation. Schizophrenia Bulletin. 2025;51(5):1193 to 1203.

What to expect

Common side effects

• Peripheral edema (swelling of ankles or feet).
• Nausea.
• Confusion.
• Constipation.
• Gait disturbance.
• Hallucinations, paradoxically, in a minority.

Serious side effects and warnings

Boxed warning. Pimavanserin carries the FDA boxed warning that antipsychotics increase the risk of death in older adults with dementia-related psychosis. This warning applies particularly here because most people treated with pimavanserin are older adults with Parkinson's disease, some of whom also have dementia.

• Increased mortality in older adults with dementia-related psychosis. The central serious concern. Risks and benefits need explicit discussion, especially when Parkinson's disease overlaps with dementia.
• QTc prolongation. Modest but real. Avoid combining with other QTc-prolonging drugs when possible.
• Confusion or worsening cognitive symptoms, especially in patients with dementia.
• CYP3A4 interactions. Strong CYP3A4 inhibitors raise pimavanserin levels; strong inducers lower them.

This isn't medical advice. Any concern about a serious side effect should be raised with a prescriber promptly.

Sexual side effects

Sexual side effects appear uncommon with pimavanserin, in contrast to dopamine-blocking antipsychotics. If they appear, it's worth raising with the prescriber.

Weight, appetite, and sleep

Pimavanserin doesn't typically cause weight gain the way dopamine-blocking antipsychotics do. Sedation is uncommon. Sleep effects vary.

Starting and dosing basics

This section is general background, not a dosing instruction. Pimavanserin comes as 17 mg tablets, taken as two tablets (total 34 mg) once daily. A 34 mg capsule form is also available. It can be taken with or without food.

Missed doses and interactions

If you miss a dose, take it when you remember unless it's almost time for the next one, then skip and carry on. Don't double up.

Pimavanserin is metabolized by CYP3A4. Strong CYP3A4 inhibitors (some antifungals, some antibiotics, some antivirals) raise levels and increase QTc risk. Strong CYP3A4 inducers lower levels. Avoid combining with other QTc-prolonging drugs when possible. The prescriber and pharmacist need a full list of medications and supplements.

Stopping and tapering

Pimavanserin can generally be stopped without a formal taper, though hallucinations may return as the drug clears. A prescriber can help plan the transition.

Pregnancy and breastfeeding

Pimavanserin is used primarily in older adults with Parkinson's disease, so pregnancy issues are uncommon. Anyone who's pregnant, planning a pregnancy, or breastfeeding should talk it through with their prescriber. This isn't medical advice.

Cost and generic availability

Pimavanserin is brand-only and expensive. Manufacturer patient assistance programs exist. Medicare Part D and many private plans cover it with prior authorization.

Common questions

Why is pimavanserin different from other antipsychotics? It doesn't block dopamine. That's the fundamental difference. Every other antipsychotic on the market works by blocking D2 receptors to some degree, which reduces psychotic symptoms but also causes movement side effects and (in Parkinson's disease) worsens tremor and rigidity. Pimavanserin works through serotonin 5-HT2A instead, sidestepping the dopamine problem.

Why is it approved only for Parkinson's disease psychosis? That's what the FDA registration trials studied. Its evidence base for schizophrenia and other psychotic conditions is more limited. Trials in dementia-related psychosis produced mixed results and haven't led to FDA approval for that indication as of June 2026.

How does the boxed warning fit here? The FDA boxed warning about increased mortality in older adults with dementia-related psychosis applies to pimavanserin as it does to all antipsychotics. Because most people prescribed pimavanserin are older adults with Parkinson's, and many have overlapping dementia, the warning has practical weight and warrants an explicit conversation.

Does it work quickly? Not usually. The fuller effect on hallucinations and delusions tends to build over four to six weeks. It isn't a rescue medication for acute psychotic agitation.

Questions to ask your prescriber

• What are we hoping this treats, and how will we know it's working?
• What are the specific risks given my age and cognitive status?
• What should I do if hallucinations don't improve?
• Are there drugs I take that interact with CYP3A4?
• If we decide to stop it later, how will symptoms return?

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes, and current as of June 8, 2026.

• U.S. Food and Drug Administration. Pimavanserin (Nuplazid) prescribing information.
• MedlinePlus, U.S. National Library of Medicine. Pimavanserin.
• National Institute of Mental Health. Mental health medications.
• American Academy of Neurology quality measurement set for Parkinson's disease.
• Cummings J, et al. Pimavanserin for patients with Parkinson's disease psychosis. Lancet. 2014;383(9916):533 to 540.
• Carolan A, et al. Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation. Schizophrenia Bulletin. 2025;51(5):1193 to 1203.